Economic Update: The Shutdown Wasn’t Free

SP Capital IQ |

Although the U.S. government is back in business, the shutdown wasn't free. The debacle dragged down growth in the fourth quarter and for the year. 



And, given the agreement expires in just a few months, the risk of another shutdown in the first quarter is very real. In this segment, Standard & Poor’s U.S. Chief Economist Beth Ann Bovino explains what lies ahead.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
MKRRF Melker Schorling AB 56.50 0.00 0.00 0

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

XY Find It

Founded by serial entrepreneur Arie Trouw, XY Findables follows a single guiding principle: customers should never lose anything important again. With over 50,000 users around the world, more than 100,000…

Knightscope

Autonomous security robots providing advanced detection capabilities at $7 per hour - aiming to define the future of security. Help #StopTheViolence.